Astellas has acquired Mitobridge in a deal worth up to $450 million. The two companies had an existing R&D collaboration in place focused on discovering and developing novel drugs that target mitochondrial function. These drug candidates have the potential to treat genetic, metabolic or neurodegenerative disorders as well as conditions of aging. MA-0211, the most advanced program emerging from the collaboration, is currently in Phase 1 clinical studies for Duchenne Muscular Dystrophy (DMD). ...